LARA
Larazotide
A synthetic octapeptide, sequence GGVLVQPG, derived from a Vibrio cholerae zonula occludens toxin. It is described in the literature as a zonulin antagonist acting at tight junctions between epithelial cells, rather than as an agonist at any receptor.
Larazotide has 10 registered human studies on ClinicalTrials.gov, reaching phase 3, covering 1,211 planned or enrolled participants across the 10 studies that published a figure. No FDA-approved product contains Larazotide. 37 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names Larazotide; the registry search is fuzzy, so every match is re-checked. None of this says whether Larazotide works or is safe.
FDA status
Research only
Human studies
10
Furthest phase
Phase 3
Papers, 10 yr
37
Readership
559
monthly average, Feb–Jul 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
Reached phase 3 or 4, not approved
10
Registered human studies
Phase 3
Furthest phase reached
1,211
Planned or enrolled participants, across 10 studies that published a figure
None
No FDA-approved product contains it
29 loose registry matches were checked and 10 confirmed — 19 named something else and were discarded. We count a study only when Larazotide is named as an intervention in it.
Registered means registered — not that the study finished, and not that it found anything. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What Larazotide is, and what it has been studied for
Larazotide is classified by ChEMBL as a protein, and appears in trial registrations under AT-2347. Its FDA substance identifier is ZN3R5560ZV.
Across 10 registered trials, it has been studied in Celiac Disease, Long COVID, Post Acute COVID-19 Syndrome and Post Acute Sequelae of COVID-19. A condition here is what a sponsor registered the trial under — it records what was investigated, not what was shown.
The trials were run by 9 Meters Biopharma, Inc. and Massachusetts General Hospital. A named commercial sponsor means a compound is in formal development; its absence does not mean the opposite, only that no company has registered a trial under its own name.
How far it got
Larazotide reached Phase 3 across 10 registered trials.
No FDA-approved product contains Larazotide. A compound can stop at any rung for commercial reasons as easily as scientific ones, and the registry does not record which.
Is anyone studying Larazotide?
Papers published each year that name Larazotide in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 0 | 0 | Yes |
| 2018 | 1 | 0 | Yes |
| 2019 | 4 | 1 | Yes |
| 2020 | 4 | 0 | Yes |
| 2021 | 12 | 1 | Yes |
| 2022 | 5 | 0 | Yes |
| 2023 | 3 | 1 | Yes |
| 2024 | 2 | 0 | Yes |
| 2025 | 8 | 0 | Yes |
| 2026 | 4 | 0 | No |
37 papers and 3 registered trials between 2017 and 2026. A paper counts when “Larazotide” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on Larazotide
37 indexed papers name Larazotide in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Targeting endothelial tight junctions to predict and protect thoracic aortic aneurysm and dissection
- Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis
- Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration
- Antibacterial hyaluronic acid hydrogel with sustained release of larazotide as effective colitis treatment
- Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide
- Larazotide acetate: a pharmacological peptide approach to tight junction regulation
- The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases
- Zonulin Antagonist, Larazotide (AT1001), As an Adjuvant Treatment for Multisystem Inflammatory Syndrome in Children: A Case Series
Collected 2026-08-02from PubMed, phrase-matched on “Larazotide” in title and abstract. Run the same search.
About Larazotide
A synthetic octapeptide, sequence GGVLVQPG, derived from a Vibrio cholerae zonula occludens toxin. It is described in the literature as a zonulin antagonist acting at tight junctions between epithelial cells, rather than as an agonist at any receptor.
- Also known as
- AT-1001 · INN-202
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.